Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Neuro-Oncology, Medicine, Duke University 2003 - 2005
  • Resident, Neurology, University of Sherbrooke 1998 - 2003
  • M.D., University of Sherbrooke 1998
• 

  Duke Appointment History

  • Associate Professor in Neurosurgery, Neurosurgery, Neurosurgery 2016 - 2017
  • Associate Professor of Neurology, Neurology, General & Community Neurology, Neurology 2013 - 2016
  • Assistant Professor of Medicine, Neurology, Clinical Science Departments 2008 - 2013
  • Medical Instructor in the Department of Medicine, Neurology, Clinical Science Departments 2005 - 2008
• Recognition
• 

  In the News

  • JUN 6, 2016

    Duke’s Poliovirus Therapy Shows Survival Benefit in Early Patients

  • MAY 16, 2016

    Poliovirus Therapy Wins 'Breakthrough' Status

  • JUN 1, 2015

    Poliovirus Study Finds That Less Is More in Brain Tumor Treatment

  • MAR 31, 2015

    Forbes

    Commentary: What ‘60 Minutes’ got right and wrong on Duke's polio virus trial against glioblastoma

  • MAR 30, 2015

    CBS “60 Minutes”

    Using polio to kill cancer

  • APR 30, 2014

    USA Today

    Poliovirus injected into brain kills student's cancer

  • AUG 21, 2013

    Al Jazeera America

    An unlikely cancer cure?

  • JUL 19, 2013

    ABC News

    Watch: Polio virus shrinks brain tumor

  • JUL 17, 2013

    News & Observer

    Tests show womans brain cancer responds to new poliovirus treatment at Duke
• Expertise
• 

  Global Scholarship

  • Expertise

    • Canada (Country) 

  • Research

    • Canada (Country) 
• Research
• 

  Selected Grants

  • Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas awarded by National Institutes of Health 2015 - 2022
  • Phase 3 randomized, open-label study to evaluate Eflornithine with Lomustine compared to Lomustine (STELLAR) alone in patients with Anaplastic Astrocytoma awarded by Orbus Therapeutics, Inc. 2016 - 2021
  • Establishing a Rationale for PVSRIPO Immunotherapy in Newly Diagnosed GBM awarded by National Brain Tumor Society 2019 - 2021
  • Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma awarded by Triphase Research and Development Corp 2016 - 2020
  • A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma awarded by Pfizer, Inc. 2016 - 2020
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2020
  • Phase 2 study of SYM004 for adult patients with recurrent glioblastoma awarded by Symphogen A/S 2015 - 2019
  • Development of a Therapeutic for Brain Tumor Immunotherapy awarded by National Institutes of Health 2018 - 2019
  • Ph1 Study of Marizomib and Bevacizumab-Naive Subjects with Grade IV Malignant Glioma awarded by Celgene Research and Development 2015 - 2019
  • Combining PVSRIPO Immunotherapy with Lomustine for the Treatment of Recurrent GBM awarded by National Brain Tumor Society 2017 - 2019
  • A Phase 1 Study of PTC in Patients with Advanced Solid Tumors awarded by PTC Therapeutics, Inc 2016 - 2017
  • CTO alone and in combination with Lomustine for Bev-niave patients awarded by Tactical Therapeutics, Inc. 2013 - 2016
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Ellingson, BM, Aftab, DT, Schwab, GM, Hessel, C, Harris, RJ, Woodworth, DC, Leu, K, Chakhoyan, A, Raymond, C, Drappatz, J, de Groot, J, Prados, MD, Reardon, DA, Schiff, D, Chamberlain, M, Mikkelsen, T, Desjardins, A, Holland, J, Ping, J, Weitzman, R, Wen, PY, and Cloughesy, TF. "Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma." Neuro Oncology 20, no. 10 (September 2018): 1411-1418.  Full Text
    • Affronti, ML, Jackman, JG, McSherry, F, Herndon, JE, Massey, EC, Lipp, E, Desjardins, A, Friedman, HS, Vlahovic, G, Vredenburgh, J, and Peters, KB. "Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma." The Oncologist 23, no. 8 (August 2018): 889-e98.  Full Text
    • Desjardins, A, Gromeier, M, Herndon, JE, Beaubier, N, Bolognesi, DP, Friedman, AH, Friedman, HS, McSherry, F, Muscat, AM, Nair, S, Peters, KB, Randazzo, D, Sampson, JH, Vlahovic, G, Harrison, WT, McLendon, RE, Ashley, D, and Bigner, DD. "Recurrent Glioblastoma Treated with Recombinant Poliovirus." The New England Journal of Medicine 379, no. 2 (July 2018): 150-161.  Full Text
    • Keir, ST, Chandramohan, V, Hemphill, CD, Grandal, MM, Melander, MC, Pedersen, MW, Horak, ID, Kragh, M, Desjardins, A, Friedman, HS, and Bigner, DD. "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models." Journal of Neuro Oncology 138, no. 3 (July 2018): 489-498.  Full Text
    • Peters, KB, Lipp, ES, Miller, E, Herndon, JE, McSherry, F, Desjardins, A, Reardon, DA, and Friedman, HS. "Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas." Journal of Neuro Oncology 137, no. 2 (April 2018): 349-356.  Full Text
    • Ghiaseddin, A, Reardon, D, Massey, W, Mannerino, A, Lipp, ES, Herndon, JE, McSherry, F, Desjardins, A, Randazzo, D, Friedman, HS, and Peters, KB. "Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma." The oncologist 23, no. 2 (February 2018): 157-e21.  Full Text
    • Cloughesy, TF, Drappatz, J, de Groot, J, Prados, MD, Reardon, DA, Schiff, D, Chamberlain, M, Mikkelsen, T, Desjardins, A, Ping, J, Holland, J, Weitzman, R, and Wen, PY. "Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy." Neuro Oncology 20, no. 2 (January 2018): 259-267.  Full Text
    • Dunn-Pirio, AM, Woodring, S, Lipp, E, Herndon, JE, Healy, P, Weant, M, Randazzo, D, Desjardins, A, Friedman, HS, and Peters, KB. "Adjunctive perampanel for glioma-associated epilepsy." Epilepsy & Behavior Case Reports 10 (January 2018): 114-117.  Full Text
    • Reap, EA, Suryadevara, CM, Batich, KA, Sanchez-Perez, L, Archer, GE, Schmittling, RJ, Norberg, PK, Herndon, JE, Healy, P, Congdon, KL, Gedeon, PC, Campbell, OC, Swartz, AM, Riccione, KA, Yi, JS, Hossain-Ibrahim, MK, Saraswathula, A, Nair, SK, Dunn-Pirio, AM, Broome, TM, Weinhold, KJ, Desjardins, A, Vlahovic, G, McLendon, RE, Friedman, AH, Friedman, HS, Bigner, DD, Fecci, PE, Mitchell, DA, and Sampson, JH. "Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma." Cancer Research 78, no. 1 (January 2018): 256-264.  Full Text
    • Wen, PY, Drappatz, J, de Groot, J, Prados, MD, Reardon, DA, Schiff, D, Chamberlain, M, Mikkelsen, T, Desjardins, A, Holland, J, Ping, J, Weitzman, R, and Cloughesy, TF. "Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy." Neuro Oncology 20, no. 2 (January 2018): 249-258.  Full Text
    • Weller, M, Butowski, N, Tran, DD, Recht, LD, Lim, M, Hirte, H, Ashby, L, Mechtler, L, Goldlust, SA, Iwamoto, F, Drappatz, J, O'Rourke, DM, Wong, M, Hamilton, MG, Finocchiaro, G, Perry, J, Wick, W, Green, J, He, Y, Turner, CD, Yellin, MJ, Keler, T, Davis, TA, Stupp, R, Sampson, JH, and ACT IV trial investigators, . "Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial." The Lancet. Oncology 18, no. 10 (October 2017): 1373-1385.  Full Text
    • Randazzo, DM, McSherry, F, Herndon, JE, Affronti, ML, Lipp, ES, Flahiff, C, Miller, E, Woodring, S, Freeman, M, Healy, P, Minchew, J, Boulton, S, Desjardins, A, Vlahovic, G, Friedman, HS, Keir, S, and Peters, KB. "A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population." Journal of Neuro Oncology 134, no. 2 (September 2017): 363-369.  Full Text
    • Affronti, ML, Woodring, S, Peters, KB, Herndon, JE, McSherry, F, Healy, PN, Desjardins, A, Vredenburgh, JJ, and Friedman, HS. "A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab." Therapeutics and Clinical Risk Management 13 (January 2017): 33-40.  Full Text
    • Desjardins, A, Vlahovic, G, and Friedman, HS. "Vaccine Therapy, Oncolytic Viruses, and Gliomas." Oncology (Williston Park, N.Y.) 30, no. 3 (March 2016): 211-218. (Review)
    • Schiff, D, Desjardins, A, Cloughesy, T, Mikkelsen, T, Glantz, M, Chamberlain, MC, Reardon, DA, and Wen, PY. "Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas." Cancer 122, no. 4 (February 2016): 582-587.  Full Text
    • Mar, N, Desjardins, A, and Vredenburgh, JJ. "CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations." Clinical cancer research : an official journal of the American Association for Cancer Research 21, no. 19 (October 2015): 4248-4250.  Full Text
    • Desjardins, A. "Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?." Nature Reviews. Neurology 11, no. 8 (August 2015): 429-430.  Full Text
    • Robinson, GW, Orr, BA, Wu, G, Gururangan, S, Lin, T, Qaddoumi, I, Packer, RJ, Goldman, S, Prados, MD, Desjardins, A, Chintagumpala, M, Takebe, N, Kaste, SC, Rusch, M, Allen, SJ, Onar-Thomas, A, Stewart, CF, Fouladi, M, Boyett, JM, Gilbertson, RJ, Curran, T, Ellison, DW, and Gajjar, A. "Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 24 (August 2015): 2646-2654.  Full Text
    • Peters, KB, Lou, E, Desjardins, A, Reardon, DA, Lipp, ES, Miller, E, Herndon, JE, McSherry, F, Friedman, HS, and Vredenburgh, JJ. "Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma." The Oncologist 20, no. 7 (July 2015): 727-728.  Full Text
    • Mitchell, DA, Sayour, EJ, Reap, E, Schmittling, R, DeLeon, G, Norberg, P, Desjardins, A, Friedman, AH, Friedman, HS, Archer, G, and Sampson, JH. "Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide." Cancer Immunology Research 3, no. 4 (April 2015): 320-325.  Full Text
    • Mitchell, DA, Batich, KA, Gunn, MD, Huang, M-N, Sanchez-Perez, L, Nair, SK, Congdon, KL, Reap, EA, Archer, GE, Desjardins, A, Friedman, AH, Friedman, HS, Herndon, JE, Coan, A, McLendon, RE, Reardon, DA, Vredenburgh, JJ, Bigner, DD, and Sampson, JH. "Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients." Nature 519, no. 7543 (March 11, 2015): 366-369.  Full Text  Open Access Copy
    • Peters, KB, West, MJ, Hornsby, WE, Waner, E, Coan, AD, McSherry, F, Herndon, JE, Friedman, HS, Desjardins, A, and Jones, LW. "Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients." Journal of Neuro Oncology 120, no. 3 (December 2014): 499-506.  Full Text
    • Brown, MC, Dobrikova, EY, Dobrikov, MI, Walton, RW, Gemberling, SL, Nair, SK, Desjardins, A, Sampson, JH, Friedman, HS, Friedman, AH, Tyler, DS, Bigner, DD, and Gromeier, M. "Oncolytic polio virotherapy of cancer." Cancer 120, no. 21 (November 2014): 3277-3286. (Review)  Full Text
    • Desjardins, A, Herndon, J, McSherry, F, Ravelo, A, Lipp, E, Healy, P, Boulton, S, Peters, K, Vlahovic, G, Sampson, J, Friedman, A, and Friedman, H. "AT-19 * SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12-v12.  Full Text
    • Desjardins, A, Herndon, J, McSherry, F, Ravelo, A, Lipp, E, Healy, P, Peters, K, Vlahovic, G, Sampson, J, Friedman, A, and Friedman, H. "AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV)." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12-v13.  Full Text
    • Desjardins, A, Sampson, J, Peters, K, Vlahovic, G, Threatt, S, Herndon, J, Boulton, S, Lally-Goss, D, McSherry, F, Lipp, E, Friedman, A, Friedman, H, Bigner, D, and Gromeier, M. "AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM)." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13-v13.  Full Text
    • Ghiaseddin, A, Dunn-Pirio, A, Peters, K, Vlahovic, G, Herndon, J, Threatt, S, Sampson, J, Friedman, A, Friedman, H, and Desjardins, A. "AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13-v13.  Full Text
    • Kang, J, Desjardins, A, Healy, P, Herndon, J, Lipp, E, Peters, K, Vlahovic, G, Sampson, J, Friedman, H, Friedman, A, and Adamson, C. "SM-02 * LEVETIRACETAM USAGE IN POST-OPERATIVE SEIZURE MANAGEMENT IN MALIGNANT GLIOMA." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v206-v206.  Full Text
    • Mowery, Y, Wright, A, Desjardins, A, Peters, K, Ranjan, T, Vlahovic, G, Friedman, H, Zomorodi, A, Kaylie, D, Adogwa, O, Nimjee, S, Sperduto, W, Chagoya, G, Fatemi, P, McLendon, R, Cummings, T, Friedman, A, Sampson, J, and Kirkpatrick, J. "MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v130-v131.  Full Text
    • Peters, K, Randazzo, D, Affronti, M, Lipp, E, McSherry, F, Herndon, J, Flahiff, C, Miller, E, Woodring, S, Freeman, M, Healy, P, Minchew, J, Boulton, S, Desjardins, A, Ranjan, T, Vlahovic, G, Jones, L, and Friedman, H. "QL-20 * PROGNOSTIC IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AND FATIGUE IN NEWLY DIAGNOSED GLIOBLASTOMA." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v182-v182.  Full Text
    • Peters, K, Reardon, D, Randazzo, D, Dutton, S, Edwards, A, Lipp, E, Herndon, J, McSherry, F, Desjardins, A, Ranjan, T, Vlahovic, G, and Friedman, H. "AT-46 * VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v18-v18.  Full Text
    • Randazzo, D, Affronti, M, Lipp, E, McSherry, F, Herndon, J, Flahiff, C, Miller, E, Woodring, S, Freeman, M, Healy, P, Minchew, J, Boulton, S, Desjardins, A, Ranjan, T, Vlahovic, G, Friedman, H, and Peters, K. "QL-21 * SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v182-v183.  Full Text
    • Ranjan, T, Peters, KB, Vlahovic, G, Watts, J, Dutton, S, Boulton, S, Lipp, E, Herndon, J, Healy, P, Miller, E, Friedman, H, Karmali, R, and Desjardins, A. "AT-48 * A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v19-v19.  Full Text
    • Reardon, D, Schuster, J, Tran, D, Fink, K, Nabors, L, Li, G, Lukas, R, Desjardins, A, Ashby, L, Duic, JP, Aneiro, L, Hawthorne, T, Green, J, Yellin, M, Davis, T, and Sampson, J. "IT-30 * ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v116-v116.  Full Text
    • Vlahovic, G, Archer, G, Lally-Goss, D, Reap, E, Batich, K, Desjardins, A, Peters, K, Ranjan, T, Healy, P, Herndon, J, Friedman, A, Friedman, H, Bigner, D, and Sampson, J. "IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)." Neuro Oncology 16, no. suppl 5 (November 1, 2014): v117-v117.  Full Text
    • Desjardins, A, Sampson, JH, Peters, KB, Ranjan, T, Vlahovic, G, Threatt, S, Herndon, JE, Boulton, S, Lally-Goss, D, McSherry, F, Friedman, AH, Friedman, HS, Bigner, DD, and Gromeier, M. "Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration." Neuro Oncol 16 Suppl 3 (July 2014): iii43-.  Full Text  Link to Item
    • Gromeier, M, Dobrikova, E, Dobrikov, M, Brown, M, Bryant, J, Threatt, S, Boulton, S, Carter, K, Herndon, J, Desjardins, A, Friedman, H, Sampson, J, Friedman, A, and Bigner, D. "Oncolytic poliovirus immunotherapy of glioblastoma." Neuro Oncol 16 Suppl 3 (July 2014): iii41-.  Full Text  Link to Item
    • Brown, MC, Dobrikova, EY, Dobrikov, MI, Walton, RW, Gemberling, SL, Nair, SK, Desjardins, A, Sampson, JH, Friedman, HS, Friedman, AH, Tyler, DS, Bigner, DD, and Gromeier, M. "Oncolytic polio virotherapy of cancer." Cancer 120, no. 21 (January 1, 2014): 3277-3286. (Review)  Full Text
    • Desjardins, A, and Friedman, HS. "Bevacizumab therapy for glioblastoma: a passionate discussion." Cns Oncology 3, no. 1 (January 2014): 1-3.  Full Text
    • Mazurowski, MA, Desjardins, A, and Malof, JM. "Imaging descriptors improve the predictive power of survival models for glioblastoma patients." Neuro Oncol 15, no. 10 (October 2013): 1389-1394.  Full Text  Link to Item
    • Cabrera, AR, Cuneo, KC, Desjardins, A, Sampson, JH, McSherry, F, Herndon, JE, Peters, KB, Allen, K, Hoang, JK, Chang, Z, Craciunescu, O, Vredenburgh, JJ, Friedman, HS, and Kirkpatrick, JP. "Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial." International Journal of Radiation Oncology, Biology, Physics 86, no. 5 (August 2013): 873-879.  Full Text
    • Lou, E, Peters, KB, Sumrall, AL, Desjardins, A, Reardon, DA, Lipp, ES, Herndon, JE, Coan, A, Bailey, L, Turner, S, Friedman, HS, and Vredenburgh, JJ. "Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma." Cancer Medicine 2, no. 2 (April 2013): 185-195.  Full Text  Open Access Copy
    • Cabrera, AR, Cuneo, KC, Desjardins, A, Sampson, JH, McSherry, F, II, JEH, Peters, KB, Allen, K, Hoang, JK, Chang, Z, Craciunescu, O, Vredenburgh, JJ, Friedman, HS, and Kirkpatrick, JP. "Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial." International Journal of Radiation Oncology Biology Physics 86, no. 5 (2013): 873-879.  Full Text
    • Jiang, X, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Quinn, JA, Austin, AD, II, JEH, McLendon, RE, and Friedman, HS. "O⁶-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma." Journal of Neuro-Oncology 114, no. 1 (2013): 135-140.  Full Text
    • Reardon, DA, Herndon, JE, Peters, KB, Desjardins, A, Coan, A, Lou, E, Sumrall, AL, Turner, S, Lipp, ES, Sathornsumetee, S, Rich, JN, Sampson, JH, Friedman, AH, Boulton, ST, Bigner, DD, Friedman, HS, and Vredenburgh, JJ. "Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients." British Journal of Cancer 107, no. 9 (October 4, 2012): 1481-1487.  Full Text  Open Access Copy
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Herndon, JE, Coan, A, Gururangan, S, Peters, KB, McLendon, R, Sathornsumetee, S, Rich, JN, Lipp, ES, Janney, D, and Friedman, HS. "Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma." Cancer 118, no. 19 (October 2012): 4759-4767.  Full Text
    • Lou, E, Sumrall, AL, Turner, S, Peters, KB, Desjardins, A, Vredenburgh, JJ, McLendon, RE, Herndon, JE, McSherry, F, Norfleet, J, Friedman, HS, and Reardon, DA. "Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series." J Neurooncol 109, no. 1 (August 2012): 63-70.  Full Text  Link to Item
    • Friedman, HS, and Desjardins, A. "Adjuvant PCV chemo hikes oligodendroglioma survival: Commentary." Oncology Report , no. JULY (July 1, 2012): 6-null.
    • Reardon, DA, Vredenburgh, JJ, Desjardins, A, Peters, KB, Sathornsumetee, S, Threatt, S, Sampson, JH, Herndon, JE, Coan, A, McSherry, F, Rich, JN, McLendon, RE, Zhang, S, and Friedman, HS. "Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma." Journal of Neuro Oncology 108, no. 3 (July 2012): 499-506.  Full Text
    • Desjardins, A, and Friedman, HS. "Neuro-oncology: Glioblastoma--community adjusts to new standard of care." Nature Reviews. Neurology 8, no. 5 (May 2012): 244-246.  Full Text
    • Cuneo, KC, Vredenburgh, JJ, Sampson, JH, Reardon, DA, Desjardins, A, Peters, KB, Friedman, HS, Willett, CG, and Kirkpatrick, JP. "Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas." International Journal of Radiation Oncology, Biology, Physics 82, no. 5 (April 2012): 2018-2024.  Full Text
    • Mason, WP, Belanger, K, Nicholas, G, Vallières, I, Mathieu, D, Kavan, P, Desjardins, A, Omuro, A, and Reymond, D. "A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression." Journal of Neuro Oncology 107, no. 2 (April 2012): 343-349.  Full Text
    • Paldino, MJ, Desjardins, A, Friedman, HS, Vredenburgh, JJ, and Barboriak, DP. "A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme." The British Journal of Radiology 85, no. 1012 (April 2012): 382-389.  Full Text
    • Desjardins, A, Reardon, DA, Coan, A, Marcello, J, Herndon, JE, Bailey, L, Peters, KB, Friedman, HS, and Vredenburgh, JJ. "Bevacizumab and daily temozolomide for recurrent glioblastoma." Cancer 118, no. 5 (March 2012): 1302-1312.  Full Text
    • Reardon, DA, Desjardins, A, Peters, KB, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, Bulusu, A, Threatt, S, Friedman, AH, Vredenburgh, JJ, and Friedman, HS. "Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma." Journal of Neuro Oncology 107, no. 1 (March 2012): 155-164.  Full Text
    • Reardon, DA, Herndon, JE, Peters, K, Desjardins, A, Coan, A, Lou, E, Sumrall, A, Turner, S, Sathornsumetee, S, Rich, JN, Boulton, S, Lipp, ES, Friedman, HS, and Vredenburgh, JJ. "Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients." Journal of Neuro Oncology 107, no. 1 (March 2012): 213-221.  Full Text
    • Desjardins, A, and Sampson, JH. "Avastin: more questions than answers. . ." Journal of Neurosurgery 116, no. 2 (February 2012): 336-340.  Full Text
    • Reardon, DA, Norden, AD, Desjardins, A, Vredenburgh, JJ, Herndon, JE, Coan, A, Sampson, JH, Gururangan, S, Peters, KB, McLendon, RE, Norfleet, JA, Lipp, ES, Drappatz, J, Wen, PY, and Friedman, HS. "Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma." Journal of Neuro Oncology 106, no. 2 (January 2012): 409-415.  Full Text
    • Sampson, JH, Schmittling, RJ, Archer, GE, Congdon, KL, Nair, SK, Reap, EA, Desjardins, A, Friedman, AH, Friedman, HS, Herndon, JE, Coan, A, McLendon, RE, Reardon, DA, Vredenburgh, JJ, Bigner, DD, and Mitchell, DA. "A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma." Plos One 7, no. 2 (January 2012): e31046-null.  Full Text  Open Access Copy
    • Vredenburgh, JJ, Desjardins, A, Kirkpatrick, JP, Reardon, DA, Peters, KB, Herndon, JE, Marcello, J, Bailey, L, Threatt, S, Sampson, J, Friedman, A, and Friedman, HS. "Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme." International Journal of Radiation Oncology, Biology, Physics 82, no. 1 (January 2012): 58-66.  Full Text
    • Desjardins, A, Reardon, DA, Peters, KB, Threatt, S, Coan, AD, Herndon, JE, Friedman, AH, Friedman, HS, and Vredenburgh, JJ. "A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma." Journal of Neuro Oncology 105, no. 3 (December 2011): 601-606.  Full Text
    • Reardon, DA, Desjardins, A, Peters, KB, Vredenburgh, JJ, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, Coan, A, Threatt, S, Friedman, AH, and Friedman, HS. "Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy." Cancer 117, no. 23 (December 2011): 5351-5358.  Full Text
    • Reardon, DA, Vredenburgh, JJ, Coan, A, Desjardins, A, Peters, KB, Gururangan, S, Sathornsumetee, S, Rich, JN, Herndon, JE, and Friedman, HS. "Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma." Journal of Neuro Oncology 105, no. 3 (December 2011): 621-627.  Full Text
    • Lou, E, Turner, S, Sumrall, A, Reardon, DA, Desjardins, A, Peters, KB, Sampson, JH, Friedman, HS, and Vredenburgh, JJ. "Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 28 (October 2011): e739-e742.  Full Text
    • Turner, SG, Peters, KB, Vredenburgh, JJ, Desjardins, A, Friedman, HS, and Reardon, DA. "Everolimus tablets for patients with subependymal giant cell astrocytoma." Expert Opinion on Pharmacotherapy 12, no. 14 (October 2011): 2265-2269. (Review)  Full Text
    • Mitchell, DA, Cui, X, Schmittling, RJ, Sanchez-Perez, L, Snyder, DJ, Congdon, KL, Archer, GE, Desjardins, A, Friedman, AH, Friedman, HS, Herndon, JE, McLendon, RE, Reardon, DA, Vredenburgh, JJ, Bigner, DD, and Sampson, JH. "Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans." Blood 118, no. 11 (September 2011): 3003-3012.  Full Text
    • Ruden, E, Reardon, DA, Coan, AD, Herndon, JE, Hornsby, WE, West, M, Fels, DR, Desjardins, A, Vredenburgh, JJ, Waner, E, Friedman, AH, Friedman, HS, Peters, KB, and Jones, LW. "Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 21 (July 2011): 2918-2923.  Full Text
    • Reardon, DA, Desjardins, A, Peters, K, Gururangan, S, Sampson, J, Rich, JN, McLendon, R, Herndon, JE, Marcello, J, Threatt, S, Friedman, AH, Vredenburgh, JJ, and Friedman, HS. "Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy." Journal of Neuro Oncology 103, no. 2 (June 2011): 371-379.  Full Text
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, Peters, KB, Herndon, JE, Marcello, J, Kirkpatrick, JP, Sampson, JH, Bailey, L, Threatt, S, Friedman, AH, Bigner, DD, and Friedman, HS. "The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 17, no. 12 (June 2011): 4119-4124.  Full Text
    • Reardon, DA, Turner, S, Peters, KB, Desjardins, A, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, Jones, LW, Kirkpatrick, JP, Friedman, AH, Vredenburgh, JJ, Bigner, DD, and Friedman, HS. "A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma." J Natl Compr Canc Netw 9, no. 4 (April 2011): 414-427. (Review)  Link to Item
    • Sampson, JH, Aldape, KD, Archer, GE, Coan, A, Desjardins, A, Friedman, AH, Friedman, HS, Gilbert, MR, Herndon, JE, McLendon, RE, Mitchell, DA, Reardon, DA, Sawaya, R, Schmittling, R, Shi, W, Vredenburgh, JJ, Bigner, DD, and Heimberger, AB. "Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma." Neuro Oncology 13, no. 3 (March 2011): 324-333.  Full Text
    • Kanaly, CW, Ding, D, Mehta, AI, Waller, AF, Crocker, I, Desjardins, A, Reardon, DA, Friedman, AH, Bigner, DD, and Sampson, JH. "A novel method for volumetric MRI response assessment of enhancing brain tumors." Plos One 6, no. 1 (January 26, 2011): e16031-null.  Full Text
    • Foo, W-C, Desjardins, A, and Cummings, TJ. "Primary intracerebral Hodgkin lymphoma with recurrence." Clinical Neuropathology 30, no. 2 (2011): 75-79.  Full Text
    • Peters, KB, Coyle, TE, Vredenburgh, JJ, Desjardins, A, Friedman, HS, and Reardon, DA. "Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy." J Neurooncol 101, no. 1 (January 2011): 155-159.  Full Text  Link to Item
    • Reardon, DA, Vredenburgh, JJ, Desjardins, A, Peters, K, Gururangan, S, Sampson, JH, Marcello, J, Herndon, JE, McLendon, RE, Janney, D, Friedman, AH, Bigner, DD, and Friedman, HS. "Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma." Journal of Neuro Oncology 101, no. 1 (January 2011): 57-66.  Full Text
    • Sathornsumetee, S, Desjardins, A, Vredenburgh, JJ, McLendon, RE, Marcello, J, Herndon, JE, Mathe, A, Hamilton, M, Rich, JN, Norfleet, JA, Gururangan, S, Friedman, HS, and Reardon, DA. "Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma." Neuro Oncol 12, no. 12 (December 2010): 1300-1310.  Full Text  Link to Item
    • Aliabadi, H, Vredenburgh, JJ, Everson, RG, Desjardins, A, Friedman, HS, McLendon, RE, Tucci, DL, and Sampson, JH. "Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration." Journal of Neuro Oncology 98, no. 3 (July 2010): 427-430.  Full Text
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Gururangan, S, Friedman, AH, Herndon, JE, Marcello, J, Norfleet, JA, McLendon, RE, Sampson, JH, and Friedman, HS. "Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma." Journal of Neuro Oncology 96, no. 2 (January 2010): 219-230.  Full Text
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Friedman, AH, Sampson, JH, McLendon, RE, Herndon, JE, and Friedman, HS. "Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy." Journal of Neuro Oncology 95, no. 3 (December 2009): 393-400.  Full Text
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Gururangan, S, Sampson, JH, Sathornsumetee, S, McLendon, RE, Herndon, JE, Marcello, JE, Norfleet, J, Friedman, AH, Bigner, DD, and Friedman, HS. "Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study." British Journal of Cancer 101, no. 12 (December 2009): 1986-1994.  Full Text  Open Access Copy
    • Perry, SL, Bohlin, C, Reardon, DA, Desjardins, A, Friedman, AH, Friedman, HS, and Vredenburgh, JJ. "Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients." Journal of Neuro Oncology 95, no. 1 (October 2009): 129-134.  Full Text
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Rich, JN, Gururangan, S, Friedman, AH, Bigner, DD, Sampson, JH, McLendon, RE, Herndon, JE, Walker, A, and Friedman, HS. "Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma." Neuro Oncology 11, no. 5 (October 2009): 556-561.  Full Text
    • Affronti, ML, Heery, CR, Herndon, JE, Rich, JN, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Friedman, AH, Bigner, DD, and Friedman, HS. "Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy." Cancer 115, no. 15 (August 2009): 3501-3511.  Full Text
    • Jones, LW, Cohen, R-R, Mabe, SK, West, MJ, Desjardins, A, Vredenburgh, JJ, Friedman, AH, Reardon, DA, Waner, E, and Friedman, HS. "Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing." Journal of Neuro Oncology 94, no. 1 (August 2009): 79-85.  Full Text
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, and Friedman, HS. "Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma." Cancer 115, no. 13 (July 2009): 2964-2970.  Full Text
    • Paldino, MJ, Barboriak, D, Desjardins, A, Friedman, HS, and Vredenburgh, JJ. "Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme." J Magn Reson Imaging 29, no. 5 (May 2009): 1199-1205.  Full Text  Link to Item
    • Reardon, DA, Egorin, MJ, Desjardins, A, Vredenburgh, JJ, Beumer, JH, Lagattuta, TF, Gururangan, S, Herndon, JE, Salvado, AJ, and Friedman, HS. "Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma." Cancer 115, no. 10 (May 2009): 2188-2198.  Full Text
    • Reardon, DA, Sathornsumetee, S, Vredenburgh, JJ, Rich, JN, Desjardins, A, Quinn, JA, Mathe, A, Gururangan, S, Friedman, AH, and Friedman, HS. "PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME." NEURO-ONCOLOGY 11, no. 2 (April 2009): 231-231.  Link to Item
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Rich, JN, Gururangan, S, Friedman, AH, Bigner, DD, Sampson, JH, McLendon, RE, Herndon, JE, Walker, A, and Friedman, HS. "Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 8 (March 2009): 1262-1267.  Full Text
    • Quinn, JA, Jiang, SX, Carter, J, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Rich, JN, Gururangan, S, Friedman, AH, Bigner, DD, Sampson, JH, McLendon, RE, Herndon, JE, Threatt, S, and Friedman, HS. "Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 15, no. 3 (February 2009): 1064-1068.  Full Text
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, and Friedman, HS. "Experience with irinotecan for the treatment of malignant glioma." Neuro Oncology 11, no. 1 (February 2009): 80-91. (Review)  Full Text
    • Desjardins, A, Reardon, DA, and Vredenburgh, JJ. "Current available therapies and future directions in the treatment of malignant gliomas." Biologics 3 (2009): 15-25.  Link to Item
    • Vredenburgh, JJ, Rich, JN, Reardon, DA, Desjardins, A, and Friedman, HS. "In reply." Journal of Clinical Oncology 26, no. 32 (November 10, 2008): 5305-null. (Letter)  Full Text
    • Desjardins, A, Reardon, DA, Herndon, JE, Marcello, J, Quinn, JA, Rich, JN, Sathornsumetee, S, Gururangan, S, Sampson, J, Bailey, L, Bigner, DD, Friedman, AH, Friedman, HS, and Vredenburgh, JJ. "Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 14, no. 21 (November 2008): 7068-7073.  Full Text
    • Gururangan, S, Krauser, J, Watral, MA, Driscoll, T, Larrier, N, Reardon, DA, Rich, JN, Quinn, JA, Vredenburgh, JJ, Desjardins, A, McLendon, RE, Fuchs, H, Kurtzberg, J, and Friedman, HS. "Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma." Neuro Oncol 10, no. 5 (October 2008): 745-751.  Full Text  Link to Item
    • Guiu, S, Taillibert, S, Chinot, O, Taillandier, L, Honnorat, J, Dietrich, PY, Maire, J-P, Guillamo, JS, Guiu, B, Catry-Thomas, I, Capelle, F, Thiebaut, A, Cartalat-Carel, S, Deville, C, Fumoleau, P, Desjardins, A, Xuan, KH, and Chauffert, B. "[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]." Revue Neurologique 164, no. 6-7 (June 3, 2008): 588-594.  Full Text
    • Guiu, S, Taillibert, S, Chinot, O, Taillandier, L, Honnorat, J, Dietrich, PY, Maire, JP, Guillamo, JS, Guiu, B, Catry-Thomas, I, Capelle, F, Thiebaut, A, Cartalat-Carel, S, Deville, C, Fumoleau, P, Desjardins, A, Xuan, KH, and Chauffert, B. "Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study." Revue Neurologique 164, no. 6-7 (June 1, 2008): 588-594.  Full Text
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Sathornsumetee, S, Rich, JN, Quinn, JA, Lagattuta, TF, Egorin, MJ, Gururangan, S, McLendon, R, Herndon, JE, Friedman, AH, Salvado, AJ, and Friedman, HS. "Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma." Neuro Oncology 10, no. 3 (June 2008): 330-340.  Full Text
    • Everson, RG, Graner, MW, Gromeier, M, Vredenburgh, JJ, Desjardins, A, Reardon, DA, Friedman, HS, Friedman, AH, Bigner, DD, and Sampson, JH. "Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma." Expert Rev Anticancer Ther 8, no. 5 (May 2008): 717-732. (Review)  Full Text  Link to Item
    • Reardon, DA, Wen, PY, Desjardins, A, Batchelor, TT, and Vredenburgh, JJ. "Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy." Expert Opinion on Biological Therapy 8, no. 4 (April 2008): 541-553. (Review)  Full Text
    • Reardon, DA, Zalutsky, MR, Akabani, G, Coleman, RE, Friedman, AH, Herndon, JE, McLendon, RE, Pegram, CN, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Guruangan, S, Boulton, S, Raynor, RH, Dowell, JM, Wong, TZ, Zhao, X-G, Friedman, HS, and Bigner, DD. "A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost." Neuro Oncology 10, no. 2 (April 2008): 182-189.  Full Text
    • Vredenburgh, J, Desjardins, A, and Reardon, D. "Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme." American Journal of Hematology/ Oncology 7, no. 4 (April 1, 2008).
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, and Friedman, HS. "In Reply:." Journal of Clinical Oncology 26, no. 6 (February 20, 2008): 1013-1013.  Full Text
    • Reardon, DA, Desjardins, A, Rich, JN, and Vredenburgh, JJ. "The emerging role of anti-angiogenic therapy for malignant glioma." Curr Treat Options Oncol 9, no. 1 (February 2008): 1-22. (Review)  Full Text  Link to Item
    • Sathornsumetee, S, Cao, Y, Marcello, JE, Herndon, JE, McLendon, RE, Desjardins, A, Friedman, HS, Dewhirst, MW, Vredenburgh, JJ, and Rich, JN. "Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 2 (January 2008): 271-278.  Full Text
    • Bota, DA, Desjardins, A, Quinn, JA, Affronti, ML, and Friedman, HS. "Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas." Ther Clin Risk Manag 3, no. 5 (October 2007): 707-715.  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Herndon, JE, Marcello, J, Reardon, DA, Quinn, JA, Rich, JN, Sathornsumetee, S, Gururangan, S, Sampson, J, Wagner, M, Bailey, L, Bigner, DD, Friedman, AH, and Friedman, HS. "Bevacizumab plus irinotecan in recurrent glioblastoma multiforme." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 30 (October 2007): 4722-4729.  Full Text
    • Sathornsumetee, S, Reardon, DA, Desjardins, A, Quinn, JA, Vredenburgh, JJ, and Rich, JN. "Molecularly targeted therapy for malignant glioma." Cancer 110, no. 1 (July 2007): 13-24. (Review)  Full Text
    • Desjardins, A, Quinn, JA, Vredenburgh, JJ, Sathornsumetee, S, Friedman, AH, Herndon, JE, McLendon, RE, Provenzale, JM, Rich, JN, Sampson, JH, Gururangan, S, Dowell, JM, Salvado, A, Friedman, HS, and Reardon, DA. "Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas." Journal of Neuro Oncology 83, no. 1 (May 2007): 53-60.  Full Text
    • Gururangan, S, Fisher, MJ, Allen, JC, Herndon, JE, Quinn, JA, Reardon, DA, Vredenburgh, JJ, Desjardins, A, Phillips, PC, Watral, MA, Krauser, JM, Friedman, AH, and Friedman, HS. "Temozolomide in children with progressive low-grade glioma." Neuro Oncology 9, no. 2 (April 2007): 161-168.  Full Text
    • Sathornsumetee, S, DesJardins, A, Reardon, DA, Rich, JN, and Vredenburgh, JJ. "Neurofibromatosis type 2." Neurology 68, no. 13 (March 27, 2007): E14-.  Full Text  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Herndon, JE, Dowell, JM, Reardon, DA, Quinn, JA, Rich, JN, Sathornsumetee, S, Gururangan, S, Wagner, M, Bigner, DD, Friedman, AH, and Friedman, HS. "Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 13, no. 4 (February 2007): 1253-1259.  Full Text
    • Badruddoja, MA, Penne, K, Desjardins, A, Reardon, DA, Rich, JN, Quinn, JA, Sathornsumetee, S, Friedman, AH, Bigner, DD, Herndon, JE, Cahill, A, Friedman, HS, and Vredenburgh, JJ. "Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme." Neuro Oncol 9, no. 1 (January 2007): 70-74.  Full Text  Link to Item
    • Reardon, DA, Quinn, JA, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS, Herndon, JE, McLendon, RE, Pegram, CN, Provenzale, JM, Dowell, JM, Rich, JN, Vredenburgh, JJ, Desjardins, A, Sampson, JH, Gururangan, S, Wong, TZ, Badruddoja, MA, Zhao, X-G, Bigner, DD, and Zalutsky, MR. "Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 47, no. 6 (June 2006): 912-918.
    • Reardon, DA, Quinn, JA, Vredenburgh, JJ, Gururangan, S, Friedman, AH, Desjardins, A, Sathornsumetee, S, Herndon, JE, Dowell, JM, McLendon, RE, Provenzale, JM, Sampson, JH, Smith, RP, Swaisland, AJ, Ochs, JS, Lyons, P, Tourt-Uhlig, S, Bigner, DD, Friedman, HS, and Rich, JN. "Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 12, no. 3 Pt 1 (February 2006): 860-868.  Full Text
    • Reardon, DA, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS, Herndon, JE, McLendon, RE, Pegram, CN, Provenzale, JM, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Gururangan, S, Badruddoja, M, Dowell, JM, Wong, TZ, Zhao, X-G, Zalutsky, MR, and Bigner, DD. "Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 24, no. 1 (January 2006): 115-122.  Full Text
    • Reardon, DA, Egorin, MJ, Quinn, JA, Rich, JN, Gururangan, S, Vredenburgh, JJ, Desjardins, A, Sathornsumetee, S, Provenzale, JM, Herndon, JE, Dowell, JM, Badruddoja, MA, McLendon, RE, Lagattuta, TF, Kicielinski, KP, Dresemann, G, Sampson, JH, Friedman, AH, Salvado, AJ, and Friedman, HS. "Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 36 (December 2005): 9359-9368.  Full Text
    • Quinn, JA, Desjardins, A, Weingart, J, Brem, H, Dolan, ME, Delaney, SM, Vredenburgh, J, Rich, J, Friedman, AH, Reardon, DA, Sampson, JH, Pegg, AE, Moschel, RC, Birch, R, McLendon, RE, Provenzale, JM, Gururangan, S, Dancey, JE, Maxwell, J, Tourt-Uhlig, S, Herndon, JE, Bigner, DD, and Friedman, HS. "Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 28 (October 2005): 7178-7187.  Full Text
    • Reardon, DA, Quinn, JA, Rich, JN, Desjardins, A, Vredenburgh, J, Gururangan, S, Sathornsumetee, S, Badruddoja, M, McLendon, R, Provenzale, J, Herndon, JE, Dowell, JM, Burkart, JL, Newton, HB, Friedman, AH, and Friedman, HS. "Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma." Cancer 104, no. 7 (October 2005): 1478-1486.  Full Text
    • Desjardins, A, Rich, JN, Quinn, JA, Vredenburgh, J, Gururangan, S, Sathornsumetee, S, Reardon, DA, Friedman, AH, Bigner, DD, and Friedman, HS. "Chemotherapy and novel therapeutic approaches in malignant glioma. (Published online)" Front Biosci 10 (September 1, 2005): 2645-2668. (Review)  Link to Item
    • Fortin, D, Desjardins, A, Benko, A, Niyonsega, T, and Boudrias, M. "Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: The Sherbrooke experience." Cancer 103, no. 12 (2005): 2606-2615.  Full Text
    • Fortin, D, Salamé, JA, Desjardins, A, and Benko, A. "Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor." American Journal of Neuroradiology 25, no. 5 (2004): 830-834.

  • Book Sections

    • Desjardins, A. "Bevacizumab and Brain Tumors." In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition, 373-381. April 24, 2018.  Full Text
    • Desjardins, A, and Friedman, HS. "Chemotherapy for gliomas." In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 76-90. March 31, 2016.  Full Text

  • Conference Papers

    • Affronti, ML, Woodring, S, Allen, K, Kirkpatrick, J, Peters, KB, Herndon, JE, McSherry, F, Healy, PN, Desjardins, A, Vredenburgh, JJ, and Friedman, HS. "Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)." October 2016.  Full Text
    • Di, K, Lloyd, GK, Abraham, V, MacLaren, A, Burrows, FJ, Desjardins, A, Trikha, M, and Bota, DA. "Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier." June 2016.  Full Text
    • Jiang, X, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Quinn, JA, Austin, AD, Herndon, JE, McLendon, RE, and Friedman, HS. "O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma." United States. August 2013.  Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.